1051 related articles for article (PubMed ID: 31046774)
1. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
Johnson B; Richert T
Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
[TBL] [Abstract][Full Text] [Related]
2. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors.
Johnson B; Richert T
Int J Drug Policy; 2015 Feb; 26(2):183-90. PubMed ID: 25465344
[TBL] [Abstract][Full Text] [Related]
3. Non-prescribed use of opioid substitution medication: Patterns and trends in sub-populations of opioid users in Germany.
Schulte B; Schmidt CS; Strada L; Götzke C; Hiller P; Fischer B; Reimer J
Int J Drug Policy; 2016 Mar; 29():57-65. PubMed ID: 26818083
[TBL] [Abstract][Full Text] [Related]
4. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
Saulle R; Vecchi S; Gowing L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
[TBL] [Abstract][Full Text] [Related]
5. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.
Richert T; Johnson B
Harm Reduct J; 2015 Feb; 12():1. PubMed ID: 25889208
[TBL] [Abstract][Full Text] [Related]
6. Diversion of methadone and buprenorphine from opioid substitution treatment: the importance of patients' attitudes and norms.
Johnson B; Richert T
J Subst Abuse Treat; 2015 Jul; 54():50-5. PubMed ID: 25744650
[TBL] [Abstract][Full Text] [Related]
7. Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies.
Betts KS; Chan G; McIlwraith F; Dietze P; Whittaker E; Burns L; Alati R
Addiction; 2016 Jul; 111(7):1214-23. PubMed ID: 26857811
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
[TBL] [Abstract][Full Text] [Related]
9. Diversion of methadone and buprenorphine from opioid substitution treatment: patients who regularly sell or share their medication.
Johnson B; Richert T
J Addict Dis; 2015; 34(1):1-17. PubMed ID: 25496247
[TBL] [Abstract][Full Text] [Related]
10. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
Larance B; Lintzeris N; Ali R; Dietze P; Mattick R; Jenkinson R; White N; Degenhardt L
Drug Alcohol Depend; 2014 Mar; 136():21-7. PubMed ID: 24461476
[TBL] [Abstract][Full Text] [Related]
11. Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective.
Johnson B; Richert T
J Psychoactive Drugs; 2014; 46(5):427-35. PubMed ID: 25364995
[TBL] [Abstract][Full Text] [Related]
12. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
13. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
[TBL] [Abstract][Full Text] [Related]
14. Patterns of non-compliant buprenorphine, levomethadone, and methadone use among opioid dependent persons in treatment.
Casati A; Piontek D; Pfeiffer-Gerschel T
Subst Abuse Treat Prev Policy; 2014 May; 9():19. PubMed ID: 24885218
[TBL] [Abstract][Full Text] [Related]
15. Opioid substitution treatment in pretrial prison detention: a case study from Geneva, Switzerland.
Favrod-Coune T; Baroudi M; Casillas A; Rieder JP; Gétaz L; Barro J; Gaspoz JM; Broers B; Wolff H
Swiss Med Wkly; 2013; 143():w13898. PubMed ID: 24186493
[TBL] [Abstract][Full Text] [Related]
16. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
Hser YI; Evans E; Huang D; Weiss R; Saxon A; Carroll KM; Woody G; Liu D; Wakim P; Matthews AG; Hatch-Maillette M; Jelstrom E; Wiest K; McLaughlin P; Ling W
Addiction; 2016 Apr; 111(4):695-705. PubMed ID: 26599131
[TBL] [Abstract][Full Text] [Related]
19. Are the Patients Ready for the Change?: An Empirical Study to Evaluate the Impact of Change in Formulation of Buprenorphine-Naloxone on Prescription Pattern, Treatment Adherence, and Patient Satisfaction.
Balhara YPS; Singh S; Sarkar S
Subst Use Misuse; 2019; 54(2):307-314. PubMed ID: 30513249
[TBL] [Abstract][Full Text] [Related]
20. Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment.
Haber PS; Elsayed M; Espinoza D; Lintzeris N; Veillard AS; Hallinan R
Drug Alcohol Depend; 2017 Dec; 181():132-139. PubMed ID: 29054032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
